Azhary A, Hajhamed NM, Osman Ali ET, Muvunyi CM, Siddig EE. Resurgent multistate measles outbreak in Sudan amidst conflict: Urgent need for vaccination and international support. Int J Infect Dis. 2025. doi:10.1016/j...
Fill Form & Download Overview Wild poliovirus (WPV) comprises 3 serotypes (1, 2, 3), which may infect and destroy spinal the lower motor neurons. PV is shed via salivary droplets and feces, and it is transmitted...
This prospective pilot study assessed the real-time epidemiology of acute respiratory infections (ARI) in Germany using self-administered, multi-pathogen antigen rapid testing among adult volunteers from the VACCELERATE...
The DAN-RSV phase 4 pragmatic randomized trial evaluated the effectiveness and safety of the bivalent RSV prefusion F protein–based vaccine (RSVpreF) in adults aged 60 years and older during the 2024–2025 season in...
The landmark study by Reichert et al. (2001) systematically analyzed the impact of Japan’s national policy to vaccinate schoolchildren against influenza on overall and pneumonia/influenza-associated mortality, spanning...
Fill Form to Download Overview Chikungunya is a viral disease with fever, severe joint pain, and rash transmitted by infected Aedes mosquitoes. The virus was first isolated in Tanzania in 1952 and has since spread...
Epidemiology Global burden: Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide, with over 200 identified HPV types, of which at least 12 are oncogenic or high-risk types. HPV causes...
Key updates for 2025-26 season Vaccine composition changes All influenza vaccines available in the United States during the 2025-26 season will be trivalent, containing hemagglutinin derived from: H1N1 component:...
Chikungunya virus disease risk in Europe is rising sharply in 2025, with locally acquired cases now confirmed in both France and Italy, and record numbers of outbreaks attributed to the spread and establishment of Aedes...
US policy shift on mRNA vaccines The US Department of Health and Human Services (HHS) announced it is winding down ~$500 million in mRNA vaccine development projects, terminating 22 government-supported BARDA...